This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-11 and is reviewed periodically as new material appears.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
== History == 4-HO-NiPT was first described in the scientific literature, as a metabolite of 4-AcO-DiPT, in 2022. Subsequently, its synthesis was described in 2023 and its pharmacology was reported in 2024. The drug was reported as a possible novel designer drug online in 2022.
Bimatoprost may be used to treat small or underdeveloped eyelashes. The medical term for this is treatment of hypotrichosis; however, the U.S. Food and Drug Administration (FDA) approval is for purely cosmetic purposes (see Prostaglandin F receptor#Clinical significance).
Synthetic oxytocin, sold under the brand name Pitocin among others, is a medication made from the peptide oxytocin. As a medication, it is used to cause contraction of the uterus to start labor, increase the speed of labor, and to stop bleeding following delivery. For this purpose, it is given by injection either into a muscle or into a vein. Oxytocin is also available in intranasal spray form for psychiatric, endocrine and weight management use as a supplement. Intranasal oxytocin works on a different pathway than injected oxytocin, primarily along the olfactory nerve crossing the blood–brain barrier to the olfactory lobe in the brain, where dense magnocellular oxytocin neurons receive the nerve impulse quickly. The natural occurrence of oxytocin was discovered in 1906. It is on the World Health Organization's List of Essential Medicines.
=== Muscle Media 2000 ("MM2K") === In 1992, Phillips moved out of his mother's home and changed the publication's format and name to Muscle Media 2000 (usually referred to as "MM2K"). The magazine published frank discussion of the underground aspects of bodybuilding such as the use of and how to smuggle steroids, and columns by writers such as The Steroid Guru Dan Duchaine, Editor-in-Chief TC Luoma, Charles Poliquin, Mike Mooney, Nutritionist Keith Klein CN CCN, and Michael Dullnig M.D. aka "Dr. X." Muscle Media 2000 debuted in March 1992 and featured bodybuilder Lee Labrada on the cover.
First, in a series of Commission decisions, Google and Amazon were fined for competition violations. In the Google Shopping case, the Commission fined Google €2.4 billion for giving preference to its own shopping results over others in Google's search, leading to huge increases in traffic for Google over rivals. In the Google Android case the Commission fined Alphabet Inc (by then Google's rebranded parent name) €4.34 billion, or 4.5% of worldwide turnover, for paying phone manufacturers to pre-install its apps, such as Google search or Chrome, as a condition to license its app marketplace Google Play. In the Google AdSense case, the Commission fined Google €1.49 billion for stopping third-party websites displaying their adverts in Google's embedded search widgets, given that it was dominant in the ad market, and unfairly excluding competitors from results. In the Amazon Marketplace case an investigation for abuse of dominant position was launched for Amazon using other traders' data to benefit its own retail business, and preferencing itself in its "Buy Box" and in access to "Prime" seller status. This was settled after Amazon committed in 2022 "not to use non-public data relating to, or derived from, the independent sellers' activities on its marketplace, for its retail business", and to not discriminate against third parties in its Buy Box and Prime services. The Digital Markets Act codifies many of these standards.
Sources: en.wikipedia.org
In 2024, the National Institute for Space Research (INPE) identified a 100% increase in the number of fires compared to the same period in 2023, with 50% of these fires recorded in the Amazon, and 32% in the Cerrado. In October 2024, MapBiomas and Amazon Environmental Research Institute (IPAM) reported that the burned area was 150% larger than in 2023, equivalent to the size of the state of Roraima, through the MapBiomas Fire Monitor. According to the Copernicus Programme, Brazil broke a record for carbon emissions, releasing 180 megatonnes of carbon into the atmosphere, largely due to the increase in fires, bringing it close to that recorded in 2007, when the country broke the previous record, with the states of Amazonas and Mato Grosso being the biggest emitters. According to INPE, in 2024, Brazil had the highest number of fires of the century.
== See also == 2,5-Dimethoxyamphetamine 2C, 3C, 4C, scaline, Ψ-PEA, 25-NB, FLY Substituted amphetamines Substituted benzofurans Substituted cathinones Substituted methoxyphenethylamine Substituted methylenedioxyphenethylamines Substituted phenethylamines Substituted tryptamines PiHKAL The Shulgin Index
==== Effects of pH ==== The uranium fraction diagrams in the presence of carbonate illustrate this further: when the pH of a uranium(VI) solution increases, the uranium is converted to a hydrated uranium oxide hydroxide; At high pH, it becomes an anionic hydroxide complex. When carbonate is added, uranium is converted to a series of carbonate complexes if the pH is increased. One effect of these reactions is increased solubility of uranium in the pH range 6 to 8, a fact that has a direct bearing on the long term stability of spent uranium dioxide nuclear fuels.
Engineered yeast-based platform Synthetic biologists are developing genetically modified live yeast that can deliver therapeutic biologic medicines. When orally delivered, these live yeast act like micro-factories and will make therapeutic molecules directly in the gastrointestinal tract. Because yeast are eukaryotic, a key benefit is that they can be administered together with antibiotics. Probiotic yeast expressing human P2Y2 purinergic receptor suppressed intestinal inflammation in mouse models of inflammatory bowel disease. A live S. boulardii yeast delivering a tetra-specific anti-toxin that potently neutralizes Toxin A and Toxin B of Clostridioides difficile has been developed. This therapeutic anti-toxin is a fusion of four single-domain antibodies (nanobodies) that potently and broadly neutralize the two major virulence factors of C. difficile at the site of infection in preclinical models. The first in human clinical trial of engineered live yeast for the treatment of Clostridioides difficile infection is anticipated in 2024 and will be sponsored by the developer Fzata, Inc.
Sources: en.wikipedia.org
2015: Edgar Savisaar, Estonian politician, had his right leg amputated. He got the disease during a trip to Thailand. 2018: Alex Smith, an American football quarterback for the Washington Football Team of the National Football League (NFL), contracted the disease after being injured during a game. He suffered an open compound fracture in his lower leg, which became infected. Smith narrowly avoided amputation and eventually returned to playing professional football in October 2020. Smith's injury and recovery is the subject of the ESPN documentary E60 Presents: Project 11. 2019: OG Maco contracted NF after an untreated rash. 2021: Irish actor Barry Keoghan revealed in 2024 that he contracted NF shortly before filming The Banshees of Inisherin and nearly had his arm amputated.
Governments have the primary public health mandate of ensuring safe food for all, however all actors in the food chain are responsible to ensure only safe food reaches the consumer, thus preventing foodborne illnesses. This is achieved through the implementation of strict hygiene rules and a public veterinary and phytosanitary service that monitors animal products throughout the food chain, from farming to delivery in shops and restaurants. This regulation includes:
The açaí palm ( ə-SY-ee, Brazilian Portuguese: [asaˈi] ; from Nheengatu asai), Euterpe oleracea, is a species of palm tree (Arecaceae) cultivated for its fruit (açaí berries, or simply açaí), hearts of palm (a vegetable), leaves, and trunk wood. Global demand for the fruit has expanded rapidly in the 21st century, and the tree is cultivated for that purpose primarily. The species is native to eastern Amazonia, especially in Brazil, mainly in swamps and floodplains. Açaí palms are tall, slender trees growing to more than 25 m (82 ft) tall, with pinnate leaves up to 3 m (9.8 ft) long. The fruit is small, round, and black-purple in color. The fruit became a staple food in floodplain areas around the 18th century, but its consumption in urban areas and promotion as a health food only began in the mid-1990s along with the popularization of other Amazonian fruits outside the region.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.